news
Novel strategy successfully suppresses HIV infection in mice
A new method, called synapse for T-cell activation (synTac), can attack HIV-infected T cells and may be a new cure for HIV and other diseases.
List view / Grid view
Drug Development
news
$7.5 million to fund senescent cell research for age-related disease
Washington University will receive $7.5 million from the NIH to study senescent cells for treatments against age-related diseases.
news
Novel method refines cryogenic electron microscopy (cyro-EM)
The statistical method known as maximum entropy could improve cryogenic electron microscopy (cryo-EM) for more effective drug treatments.
news
Highly potent antiviral against dengue could prevent spread of virus
A new antiviral has shown promise against the dengue virus in mice and has the potential to be used as a preventative measure.
news
Mission Therapeutics receives $500k grant for Parkinson’s research
Mission Therapeutics was granted $500,000 from the The Michael J Fox Foundation for Parkinson’s Research for DUB inhibitor testing.
news
Discovery unveils genetic risk factor shared by Alzheimer’s and COVID-19
Scientists have identified the OAS1 gene as a risk factor for both Alzheimer's disease and COVID-19, suggesting potential drug targets.
article
Are computer simulations the future of rapid COVID-19 drug development?
Researchers have visualised SARS-CoV-2 protein dynamics using in silico methods. In this article, Navodya Roemer explains how a team from the University of Warwick developed a computational strategy that could assist scientists in the production of new treatments and drugs for COVID-19.
news
Pre-clinical trials to test if psychedelic drugs reduce alcohol consumption
Landmark pre-clinical studies to investigate whether psychedelic derivatives can reduce alcohol consumption have been initiated.
news
Psilera to collaborate with NIDA on pre-clinical psychedelic studies
Psilera will participate in two studies with the National Institute on Drug Abuse to combat addiction using a novel DMT formulation.
article
AI & Informatics: Drug discovery and development – industry survey infographic
View Drug Target Review's new infographic on the use of AI and informatics within early therapeutic development here.
news
Psilocybin spurs growth of neural connections lost in depression in vivo
Research from Yale University has shown that psilocybin, given to mice, triggered an increase in connections between neurons.
article
Targeting SARS-CoV-2 replication with inhibitors of lipid metabolism
One approach towards efficient drug targeting efforts for COVID-19 is to repurpose medicines developed for other diseases. Here, Professor Christopher Basler outlines a recent study, published in Cell Reports, where scientists from the Institute for Biomedical Sciences at Georgia State University, US, in collaboration with industry partners, developed assays to…
news
New measures to minimise animal testing to be implemented in Europe
The European Medicines Agency is promoting three principles – replace, reduce and refine – to reduce animal testing in medicine development.
article
High-throughput 3D cell migration assays in organ-on-a-chip technologies
Organ-on-a-chip models can provide an alternative to cell cultures, animal models and traditional assays. In this article, Dr Désirée Goubert, Thomas Olivier, Luuk de Haan and Dr Lenie van den Broek explore the advantages of organ-on-a-chip technologies and how they can enable the in vitro study of three-dimensional (3D) cell migration in…
article
Targeting disease pathways to treat ulcerative colitis – beyond corticosteroid use
Dr Chetan Karyekar, Compound Development Team Leader at The Janssen Pharmaceutical Companies of Johnson & Johnson (J&J), explains how targeting underlying immune pathways can open the door to effectively treating more inflammatory bowel disease (IBD) patients by reducing or eliminating the chronic use of corticosteroids.
